


Amendments to the Claims:

This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims:

1. (Currently Amended) A compound of formula I




wherein

R_a is H; C₁₋₄alkyl; or C₁₋₄alkyl substituted by OH, NH₂, NHC₁₋₄alkyl or N(di-C₁₋₄alkyl)₂;

R_b is H; halogen; C₁₋₆alkyl; or C₁₋₆alkoxy, and

R is a radical of formula (a)



(a)

wherein


R₁ is piperazine; and

each of R₂ and R₄, independently, is H; halogen; C₁₋₄alkyl; C₁₋₄alkoxy; CF₃; nitrile; nitro or amino, or a salt thereof.

2. (Original) A compound according to claim 1 wherein R_a is H, methyl, ethyl, or isopropyl, or a salt thereof.
3. (Previously Presented) A compound according to claim 1 wherein R_b is H, Cl, methyl or ethyl, or a salt thereof.
4. (Previously Presented) A compound according to claim 1 wherein R₁ is a piperazinyl, substituted on a ring nitrogen or on a ring carbon, or a salt thereof.


5. (Previously Presented) A compound according claim 1 wherein R₂ is H, Cl, F, CF₃, nitrile, nitro or amino, or a salt thereof.

6. (Previously Presented) A process for the preparation of a compound of formula I according to claim 1, which process comprises reacting a compound of formula II



wherein R_a and R_b are as defined in claim 1,

with a compound of formula III



wherein R is as defined in claim 1,

and, where required, converting the resulting compound of formula I obtained in free form to a salt form or vice versa, as appropriate.

7. (Previously Presented) A compound of formula I of claim 1, in free form or in a pharmaceutically acceptable salt form for use as a pharmaceutical.

8. (Previously Presented) A pharmaceutical composition comprising a compound of formula I of claim 1, in free form or in a pharmaceutically acceptable salt form, in association with a pharmaceutically acceptable diluent or carrier therefor.

9. (Cancelled).

10. (Previously Presented) A method for preventing or treating acute or chronic transplant rejection in a subject in need of such treatment, which method comprises administering to said subject an effective amount of a compound of formula I of claim 1 or a pharmaceutically acceptable salt thereof.

11. (Currently Amended) A method for preventing or treating T-cell mediated inflammatory or autoimmune diseases acute or chronic transplant rejection, psoriasis, or uveitis, in a subject in need of such treatment, which method comprises

administering to said subject an effective amount of a compound of formula I of claim 1 or a pharmaceutically acceptable salt thereof.